Close Menu

This Week in Science

In this week's Science Translational Medicine, scientists from the University of Freiburg discuss immune checkpoint inhibitor-based cancer treatments targeting programmed death receptor-1 or programmed death ligand-1 (PD-L1), and the need to consider unique tumor mutations that modulate drug responses when designing combination treatments.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.